Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Early identification of asymptomatic subjects at increased risk of heart failure and cardiovascular events: progress and future directions.

Coller JM, Campbell DJ, Krum H, Prior DL.

Heart Lung Circ. 2013 Mar;22(3):171-8. doi: 10.1016/j.hlc.2012.09.009. Epub 2012 Nov 13. Review.

PMID:
23154198
2.

Stage B heart failure: rationale for screening.

Atherton JJ.

Heart Fail Clin. 2012 Apr;8(2):273-83. doi: 10.1016/j.hfc.2011.11.003. Review.

PMID:
22405666
3.

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S.

Circulation. 1996 Aug 15;94(4):690-7.

4.

The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening.

Wang TJ, Levy D, Benjamin EJ, Vasan RS.

Ann Intern Med. 2003 Jun 3;138(11):907-16. Review.

PMID:
12779301
5.

Health gains by using natriuretic peptides in diagnosis, prognosis and treatment.

Richards M, Troughton R, Lainchbury J, Doughty R, Wright S.

Scand J Clin Lab Invest Suppl. 2005;240:129-37.

PMID:
16112970
6.

Proteomic analysis of coronary sinus serum reveals leucine-rich α2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure.

Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, McDonald KM, Baugh JA.

Circ Heart Fail. 2011 Mar;4(2):188-97. doi: 10.1161/CIRCHEARTFAILURE.110.952200. Epub 2011 Jan 31.

7.

From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.

Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK; SHAPE Task Force.

Am J Cardiol. 2006 Jul 17;98(2A):2H-15H. Epub 2006 Jun 12. Review.

PMID:
16843744
8.

Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group.

Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group.

Circulation. 2008 May 13;117(19):2544-65. doi: 10.1161/CIRCULATIONAHA.107.188965. Epub 2008 Apr 7.

9.

Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide.

Freitag MH, Vasan RS.

Heart Fail Monit. 2003;4(2):38-44. Review.

PMID:
14724717
10.

[Cardiac failure in hypertensive cardiopathy].

Verdecchia P.

Ital Heart J. 2000 Jun;1 Suppl 2:72-7. Review. Italian.

PMID:
10905132
11.

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.

Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P.

Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16.

12.

Screening for ventricular remodeling.

Lee DS, Wang TJ, Vasan RS.

Curr Heart Fail Rep. 2006 Apr;3(1):5-13. Review.

PMID:
16684491
13.

Novel markers for heart failure diagnosis and prognosis.

Lee DS, Vasan RS.

Curr Opin Cardiol. 2005 May;20(3):201-10. Review.

PMID:
15861008
14.

[Modern therapy of cardiac insufficiency].

Stojsić D, Jelkić N.

Med Pregl. 1999 Mar-May;52(3-5):113-24. Review. Croatian.

PMID:
10518395
15.

Screening: the new frontier in heart failure management.

McGrady M, Krum H.

Cardiovasc Ther. 2009 Spring;27(1):1-3. doi: 10.1111/j.1755-5922.2009.00075.x. No abstract available.

PMID:
19207473
16.
17.

[Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].

Tarantini L, Cioffi G, Di Lenarda A, Valle R, Pulignano G, Del Sindaco D, Frigo G, Soravia G, Tessier R, Catania G.

G Ital Cardiol (Rome). 2008 Dec;9(12):835-43. Italian.

PMID:
19119693
18.

Lethal outcomes in patients with symptomatic heart failure developed after Q-wave myocardial infarction.

Zaliūnas R, Babarskiene MR, Kavoliūniene A, Slapikiene B, Luksiene D, Slapikas R, Vencloviene J.

Medicina (Kaunas). 2004;40(2):141-8. English, Lithuanian.

19.

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM.

Eur J Heart Fail. 2011 Oct;13(10):1087-95. doi: 10.1093/eurjhf/hfr079. Epub 2011 Jun 30.

20.

[Brain natriuretic peptide (BNP) in coronary insufficiency: relationship with left ventricular filling and exercise tolerance].

Logeart D, Gambert A, Beyne P, Guiti C, Geyer C, Bourgoin P, Alonso C, Ennezat PV, Gourgon R, Cohen-Solal A.

Ann Cardiol Angeiol (Paris). 1999 Sep;48(7):523-8. French.

PMID:
12555377

Supplemental Content

Support Center